Release Summary

Investors reminded of upcoming lead plaintiff deadline in securities class litigation for investors who acquired the securities of Novo Nordisk A/S (NYSE:NVO) between 2/5/2015-10/27/16.

Lieff Cabraser Heimann & Bernstein, LLP